title: Chronic ouabain treatment enhances cardiac myosin ATPase activity in rats.
abstract: 1. Chronic ouabain administration increases blood pressure and produces a positive inotropic effect. However, the temporal changes capable of affecting both arterial and ventricular pressures and myosin ATPase activity during the induced hypertension have not been determined. 2. The aim of the present study was to investigate the time-course of the induction of hypertension to define when changes occur in Wistar rats treated with 25 mg/kg per day, s.c., ouabain for 3, 7, 15 or 30 days. 3. In anaesthetized rats, diastolic blood pressure increased after 7 days treatment with ouabain and after 15 and 30 days treatment, increases were observed in systolic blood pressure, left ventricular systolic pressure and myosin ATPase activity. After 15 days treatment, heart rate (HR) also increased, but after 30 days treatment HR returned to control levels. However, only after 30 days treatment did the left ventricular positive and negative first derivatives of intraventricular pressure (dP/dt(max) and dP/dt(min), respectively) increase. Increased arterial and left ventricular systolic pressures and myosin ATPase activity observed after 15 days treatment maintained similar levels as those after 30 days treatment. 4. The results suggest that changes in arterial and left ventricular pressures, HR and myosin ATPase activity induced by chronic ouabain treatment are time dependent, increasing after 15 days treatment. After 30 days treatment, the increase in systolic and diastolic arterial and ventricular pressures remained stable, as did inotropism. Normalization of HR after 30 days treatment suggests that during the period from Day 16 to Day 30 ouabain-induced hypertension is dependent, at least in part, on increased sympathetic activity.
authors.affiliation: Department of Physiological Sciences, Federal University of Espirito Santo, Vitória, Espírito Santo, Brazil. ale_padilha@hotmail.com
authors.forename: Alessandra S
authors.initials: AS
authors.lastname: Padilha
authors.forename: Cleci M
authors.initials: CM
authors.lastname: Moreira
authors.forename: Eduardo F
authors.initials: EF
authors.lastname: Meira
authors.forename: Fabiana D M
authors.initials: FD
authors.lastname: Siman
authors.forename: Ivanita
authors.initials: I
authors.lastname: Stefanon
authors.forename: Dalton V
authors.initials: DV
authors.lastname: Vassallo
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D004789:Enzyme Activation / Q000187:drug effects / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology; D008297:Male; D009206:Myocardium / Q000201:enzymology*; D009218:Myosins / Q000235:genetics / Q000378:metabolism*; D010042:Ouabain / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D010042:Ouabain; D009218:Myosins